SCOTCH PLAINS, N.J. — September 17, 2025 — Leads & Copy — Navigator Medicines Inc. announced further data from a Phase 1a study of its lead therapeutic candidate, NAV-240, showing a good safety and tolerability profile across dose cohorts in 40 healthy volunteers. The company also announced that the Phase 1b study is fully enrolled, with data expected in early 2026, and further clinical development of NAV-240 is slated to begin in early 2026.
NAV-240 is a bispecific antibody designed to inhibit overactivation of the immune system and inflammation by blocking OX40L and TNFα. The concentration of NAV-240 in the bloodstream increased in proportion to the dose, supporting predictable dosing in further development. Concentration-dependent reductions were noted in thymus and activation-regulated chemokine (TARC), a signaling protein associated with several inflammatory skin conditions.
According to Navigator Medicines CEO Tosh Butt, the data provides a strong foundation for the continued clinical development of NAV-240 as a potentially best-in-class therapy for complex inflammatory disorders like hidradenitis suppurativa (HS).
Navigator Medicines is also advancing NAV-242, a next-generation engineered anti-OX40L/TNFα antibody with half-life-extension.
Business or Investor Inquiries: Mark McLaughlin, info@navigatormedicines.com; Media Inquiries: Arran Attridge, arran@attridgecomms.com
Source: Navigator Medicines Inc.
